Koers ASLAN Pharmaceuticals Limited Taipei Exchange
Aandelen
6497
KYG054241099
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 293 mln. 9,13 mln. 8,39 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -2,36 mld. -73,49 mln. -67,46 mln. | Nettowinst (verlies) 2025 * | -1,77 mld. -55,3 mln. -50,77 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-0,12
x | K/w-verhouding 2025 * |
-0,17
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Carl Firth
FOU | Founder | 51 | 01-01-10 |
Kiran Asarpota
DFI | Director of Finance/CFO | 45 | 01-11-10 |
Chief Tech/Sci/R&D Officer | - | 15-03-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Robert Hoffman
BRD | Director/Board Member | 58 | 30-10-18 |
Andrew Howden
CHM | Chairman | 64 | 01-04-16 |
Carl Firth
FOU | Founder | 51 | 01-01-10 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+7,60% | 111 mld. | |
+11,36% | 106 mld. | |
-12,46% | 22,24 mld. | |
+0,44% | 21,25 mld. | |
-4,18% | 18,97 mld. | |
-37,85% | 18,52 mld. | |
-9,02% | 16,81 mld. | |
+38,23% | 12,54 mld. | |
-24,40% | 8,09 mld. |